Korenfeld, Michael S. http://orcid.org/0000-0003-1804-5525
Robertson, Stella M.
Stein, Jerry M.
Evans, David G.
Rauchman, Steven H.
Sall, Kenneth N.
Venkataraman, Subha
Chen, Bee-Lian
Wuttke, Mark
Burns, William
Funding for this research was provided by:
Novartis
Encore Vision, Inc., Fort Worth, Texas
Article History
Received: 19 May 2020
Revised: 15 November 2020
Accepted: 18 December 2020
First Online: 29 January 2021
Compliance with ethical standards
:
: MSK: Consultant—Novartis; Financial support—Novartis and Encore Vision, Inc. SMR: Consultant—Encore Vision, Inc.; Financial support – Encore Vision, Inc. and Novartis. JMS: Consultant – Encore Vision, Inc. DGE: Financial support – Encore Vision, Inc., Allergan and Orasys. KNS: Consultant - Kala Pharmaceuticals, Novaliq, Ocular Therapeutix, Sun Pharma; Financial Support – Encore Vision, Inc., Novartis and Valeant. SV, BC, and MW: - Employees of Novartis. WB: – Employee of Encore Vision, Inc.